文献速递冠心病心力衰竭与心肌病

阿利西尤单抗在合并心衰病史的急性冠脉综合征患者中的疗效:ODYSSEY OUTCOMES 事后分析

Alirocumab after acute coronary syndrome in patients with a history of heart failure.
PubMed 文献 · Eur Heart J · 2022-01-01

该研究为 ODYSSEY OUTCOMES 试验的事后分析,纳入 18 924 例近期发生急性冠脉综合征且接受强化或最大耐受剂量他汀治疗的患者,其中 2815 例(14.9%)有心衰病史。结果显示,阿利西尤单抗在无心衰病史患者中显著降低主要不良心血管事件(HR 0.78,95%CI 0.70-0.86,P<0.0001),但在有心衰病史患者中未见获益(HR 1.17,95%CI 0.97-1.40,P=0.10),交互作用 P=0.0001;两组心衰住院均未减少。

要点

  • 阿利西尤单抗降低 MACE 的获益仅见于无心衰病史的 ACS 患者。
  • 有心衰病史的 ACS 患者使用阿利西尤单抗未显著降低 MACE。
  • 阿利西尤单抗未减少任何组别的心衰住院。

核心结论

  • 阿利西尤单抗在无心衰病史患者中降低 MACE,但在有心衰病史患者中未观察到获益。
  • 阿利西尤单抗未减少心衰住院,无论整体还是按心衰病史分组。
  • 有心衰病史的 ACS 患者为高危群体,似乎不能从 ACS 后 PCSK9 抑制中获益。

研究设计与样本

  • ODYSSEY OUTCOMES 试验的事后分析,纳入 18 924 例近期急性冠脉综合征且接受强化或最大耐受剂量他汀治疗的患者。
  • 按有无心衰病史分组,比较主要不良心血管事件(MACE)和预设次要结局心衰住院。
  • 共 2815 例(14.9%)患者有心衰病史。

主要发现

  • 阿利西尤单抗在有无心衰病史患者中降低低密度脂蛋白胆固醇和脂蛋白(a)的幅度相似。
  • 整体人群阿利西尤单抗降低 MACE(HR 0.85,95%CI 0.78-0.93,P=0.0001)。
  • 无心衰病史患者中阿利西尤单抗降低 MACE(HR 0.78,95%CI 0.70-0.86,P<0.0001)。
  • 有心衰病史患者中阿利西尤单抗未降低 MACE(HR 1.17,95%CI 0.97-1.40,P=0.10),交互作用 P=0.0001。
  • 阿利西尤单抗未减少心衰住院,整体及按心衰病史分组均无减少。

临床怎么用

  • 对于近期 ACS 且无心力衰竭病史的患者,可考虑使用阿利西尤单抗以降低 MACE 风险。
  • 对于有心衰病史的 ACS 患者,阿利西尤单抗的获益未得到证实,决策需个体化。

局限性

  • 该分析为 ODYSSEY OUTCOMES 试验的事后分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Patients with heart failure (HF) have not been shown to benefit from statins. In a post hoc analysis, we evaluated outcomes in ODYSSEY OUTCOMES in patients with vs. without a history of HF randomized to the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab or placebo. METHODS AND RESULTS: Among 18 924 patients with recent acute coronary syndrome (ACS) receiving intensive or maximum-tolerated statin treatment, the primary outcome of major adverse cardiovascular events (MACE) was compared in patients with or without a history of HF. The pre-specified secondary outcome of hospitalization for HF was also analysed. Overall, 2815 (14.9%) patients had a history of HF. Alirocumab reduced low-density lipoprotein cholesterol and lipoprotein(a) similarly in patients with or without HF. Overall, alirocumab reduced MACE compared with placebo [hazard ratio (HR): 0.85; 95% confidence interval (CI): 0.78-0.93; P = 0.0001]. This effect was observed among patients without a history of HF (HR: 0.78; 95% CI: 0.70-0.86; P < 0.0001), but not in those with a history of HF (HR: 1.17; 95% CI: 0.97-1.40; P = 0.10) (Pinteraction = 0.0001). Alirocumab did not reduce hospitalization for HF, overall or in patients with or without prior HF. CONCLUSION: Alirocumab reduced MACE in patients without a history of HF but not in patients with a history of HF. Alirocumab did not reduce hospitalizations for HF in either group. Patients with a history of HF are a high-risk group that does not appear to benefit from PCSK9 inhibition after ACS.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. White, Schwartz, Szarek, et al. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022. PMID: 34922353. doi:10.1093/eurheartj/ehab804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。